Startups
Zambon
Edit

Zambon

Trusted
http://www.zambon.com/
Last activity: 07.10.2026
Active
Categories: CareDevelopmentFamilyHealthTechManagementManufacturingMedTechProductProductionResearch
Zambon is a modern healthcare company founded on the history and values of an Italian family and committed to innovating cure & care to improve patients’ lives. Present in Europe, America and Asia with over 2,700 employees and manufacturing units in Italy, Switzerland, France, China and Brazil, in 2021 the Group revenues amounted to 696 million euros. The Pharma company, with its 23 subsidiaries and products commercialized in 87 countries, has taken a new role in the industry. In addition to pain and diseases of the respiratory system and urological system, Zambon is establishing a global pipeline and introducing important treatments for serious diseases such as Parkinson’s Disease, Cystic Fibrosis, BOS and NCFB. Zambon produces high quality products thanks to the management of the whole production chain which involves Zach (Zambon Chemicals), a privileged partner for API, custom synthesis and generic products. Recognizing the ever-growing importance of innovative technologies and the digitalization of healthcare, Zambon complements the offering of medicines with modern health solutions: Zcube - Zambon Research Venture – actively scouts and supports the growth of innovative projects and startups. Among them, in 2018 Zcube founded Careapt, a new startup which develops integrated Hi-Tech/Hi-Touch solutions for chronic disease management. Zambon was established in 1906 in Vicenza and is headquartered in Milan within OpenZone, the scientific campus where knowledge is shared between partners in the field of Healthcare, founded with the aim to transform research into enterprise.
Followers
2.64K
Followers
189.94K
Website visits
9.9K /mo.
Mentions
11

Overview

Location
Italy, Lombardy, Bresso
Employees
1001-5000
Founded date
1906

Mentions in press and media 11

DateTitleDescription
Sign up to seeSign up to seeSign up to see
Dec 15, 2025EpilepsyGTx Secures $33M to Pioneer Single-Dose Gene Therapy for Refractory EpilepsyEpilepsyGTx just raised $33 million. This Series A funding will fuel clinical trials. Their focus? A gene therapy for focal refractory epilepsy (FRE). FRE impacts millions globally. Current treatments often fail. EpilepsyGTx offers a potent...
Dec 12, 2025EpilepsyGTx Secures $33 Million Series A To Advance Single-Dose Gene Therapy For Focal Refractory EpilepsyEpilepsyGTx, a biotechnology company focused on developing gene therapies for refractory epilepsy, has raised $33 million in a Series A financing to advance its lead program, EPY201, into first-in-human clinical trials. The funding will sup...
Dec 10, 2025Gene therapy for severe epilepsy moves forward with EpilepsyGTx’s €28 million fundingEpilepsyGTx, a Cambridge-based BioTech startup focused on research and development of gene therapies to treat refractory epilepsy, today announced it has raised €28 million ($33 million) in Series A financing to advance its lead programme E...
Sep 3, 2024Parkinson’s Disease Drug Market: Trends, Growth, and SegmentationShare Tweet Share Share Email Parkinson’s disease, a progressive neurodegenerative disorder characterized by motor symptoms such as tremors, rigidity, and bradykinesia, affects millions of individuals worldwide. As the global population age...
Nov 10, 2021Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in SwitzerlandBASEL, Switzerland, Nov. 10, 2021 /PRNewswire/ -- Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Zambon Switzerland (Zambon), under which the company grants ...
Oct 5, 2021Акселераторы, о которых должны знать MedTech-стартапыАкселераторы, о которых должны знать MedTech-стартапы
Oct 5, 2021Must-know accelerators for MedTech-startupsMust-know accelerators for MedTech-startups
Oct 5, 2021Акселераторы, о которых должны знать MedTech-стартапыАкселераторы, о которых должны знать MedTech-стартапы
Jul 25, 2019Zambon Acquires Breath Therapeutics, For Up To €500MZambon, an Italian multinational pharmaceutical company, acquired Breath Therapeutics, a biopharmaceutical company developing an innovative inhalation therapy for Bronchiolitis Obliterans Syndrome (BOS), for € 140m (up to total € 500m subje...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In

FAQ about Zambon

When was Zambon founded?

Zambon was founded in 1906.

What has the press written about Zambon?

Parsers VC has collected 11 articles mentioning Zambon, among them “EpilepsyGTx Secures $33M to Pioneer Single-Dose Gene Therapy for Refractory Epilepsy” (Dec 15, 2025) and “EpilepsyGTx Secures $33 Million Series A To Advance Single-Dose Gene Therapy For Focal Refractory Epilepsy” (Dec 12, 2025).

Is Zambon still active?

Yes, Zambon is active; its latest activity on Parsers VC dates from Oct 7, 2026.